Sevenfact Market Report 2026

Sevenfact Market Overview

• The Sevenfact market growth in the historic period has been driven by advancements in recombinant clotting factor development, improved survival rates in hemophilia patients • Market expansion is supported by increasing adoption of personalized hemophilia therapies, rising demand for safer recombinant products • Growth Driver: The Impact Of Increasing Blood Disorder Prevalence On Market Growth • Market Trend: Expanded Formulation Strengths Drive Innovation In Sevenfact Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sevenfact Market?

Sevenfact refers to a recombinant coagulation factor VIIa (eptacog beta) used for the treatment and control of bleeding episodes in patients with hemophilia A or B with inhibitors. It is designed to help manage bleeding by promoting blood clot formation. The main indications for sevenfact are hemophilia A and hemophilia B. Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, leading to difficulty in blood clotting and frequent bleeding episodes. Distribution channels include hospital pharmacies and specialty pharmacies. End uses encompass hospitals, clinics, ambulatory care, and home care.

What Is The Sevenfact Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of personalized hemophilia therapies, rising demand for safer recombinant products, expansion of home-based bleeding management, growing focus on prophylactic treatment strategies, innovation in next-generation coagulation agents. Major trends in the forecast period include increasing adoption of recombinant coagulation factors, rising focus on inhibitor hemophilia management, growing demand for on-demand bleeding control therapies, expansion of precision hemostasis treatments, enhanced focus on rapid-acting clotting agents.

Global Sevenfact Market Segmentation

1) By Indication: Hemophilia A, Hemophilia B 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies 3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Sevenfact Market?

The increasing prevalence of blood disorders is expected to propel the growth of the sevenfact market going forward. Blood disorders are conditions that impact the components or functions of blood, such as red blood cells, white blood cells, platelets, or plasma. The increasing prevalence of blood disorders can be attributed to various factors, including an aging population, genetic predispositions, chronic diseases, and infections or inflammatory conditions. Sevenfact helps blood disorders by promoting effective blood clotting in patients with hemophilia A or B with inhibitors, thereby controlling bleeding episodes and reducing the risk of severe complications. For instance, in April 2024, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health agency, there were 2.8 million visits to physician offices for anemia as the primary diagnosis, with 6,021 deaths, resulting in a mortality rate of 1.8 deaths per 100,000 population. Therefore, the increasing prevalence of blood disorders is driving the growth of the sevenfact industry. The rising government healthcare spending is expected to propel the growth of the sevenfact market going forward. Government healthcare spending involves the allocation of public funds by governments to support healthcare services, programs, and infrastructure for their citizens. Rising government healthcare spending is driven by factors such as an aging population, increasing prevalence of chronic diseases, advancements in medical technology, and the need for improved healthcare infrastructure and services. Sevenfact can help manage rising government healthcare spending by offering a cost-effective treatment for hemophilia patients with inhibitors, potentially lowering long-term expenses related to frequent hospitalizations and emergency care while enhancing patient outcomes and quality of life. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health expenditure is projected to reach $344 billion in 2023, reflecting a modest growth of 2.8% compared to the previous year. Therefore, the rising government healthcare spending is driving the growth of the sevenfact industry.

Key Players In The Global Sevenfact Market

Major companies operating in the sevenfact market are HEMA Biologics Inc.

Global Sevenfact Market Trends and Insights

Major companies operating in the Sevenfact market are focusing on technological advancements, such as recombinant protein formulation optimization, to gain a competitive advantage. This technology involves engineering the protein composition of coagulation factor VIIa to create multiple dosage strengths that enhance dosing flexibility, simplify administration, and improve patient adherence in prescription delivery. For instance, in June 2024, LFB S.A., a France-based biopharmaceutical company, launched a new 2 mg dosage strength of SEVENFACT (coagulation factor VIIa, recombinant-jncw). This launch features a co-packaged 3 mL prefilled sterile water syringe for easier reconstitution, allows precise dosing for moderate bleeds, and reduces the number of vials required per administration. These improvements increase convenience for patients and healthcare providers while supporting efficient prescription delivery and inventory management.

Regional Insights

North America was the largest region in the sevenfact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sevenfact Market?

The sevenfact market consists of sales of sevenfact injections, sevenfact lyophilized powder, and sevenfact prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sevenfact Market Report 2026?

The sevenfact market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sevenfact industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.